ResMarkerDB: a database of biomarkers of response to antibody therapy in breast and colorectal cancer
Creators: name: Granado, Judith Pérez
name: Piñero, Janet
name: Furlong, Laura I.
Publisher: name: F1000 Research Limited
Year: 2019

description: <i>Abstract</i><br>The clinical efficacy of therapeutic monoclonal antibodies for breast and colorectal cancer has greatly contributed to the improvement of patients’ outcomes by individualizing their treatments [1]. However, primary or acquired resistance to treatment reduce its efficacy [2,3]. In this context, the identification of biomarkers predictive of drug response would support research and development of alternative treatments [4]. Currently, several molecular biomarkers of treatment response for breast and colorectal cancer have been described. However, this information is scattered across several resources and not properly integrated hindering its potential use. Therefore, there is a need for resources that offer biomarker data in a harmonized manner to support the identification of actionable biomarkers of response to treatment in cancer. ResMarkerDB was developed as a comprehensive resource of biomarkers of drug response in colorectal and breast cancer. It integrates these data from existing repositories, and new data extracted and curated from the literature (referred as ResCur). The database contains more than 500 biomarker-drug-tumour associations. ResMarkerDB provides a web interface (http://www.resmarkerdb.org) to facilitate the exploration of the current knowledge of biomarkers of response in breast and colorectal cancer. It aims to enhance translational research efforts in identifying actionable biomarkers of drug response in cancer.<br><br><i>References</i> <br>[1] Chiavenna,S.M. et al. (2017) State of the art in anti-cancer mAbs. J. Biomed. Sci., 24, 15. <br>[2] Pruneri,G. et al. (2016) Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients. Curr. Opin. Oncol., 28, 476–483. <br>[3] Bronte,G. et al. (2015) New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Oncotarget, 6. <br>[4] Bossuyt,P.M. and Parvin,T. (2015) Evaluating Biomarkers for Guiding Treatment Decisions. EJIFCC, 26, 63–70. <br><br><i>Funding</i> <br>This work was supported by “Instituto de Salud Carlos III- Fondo Europeo de Desarrollo Regional” [grant numbers: PIE15/00008, CP10/00524, CPII16/00026];, “Instituto de Salud Carlos III- Fondo Social Europeo” [FI18/00034]; and the European Commission Horizon 2020 Programme 2014- 2020 under grant agreements MedBioinformatics [grant number: 634143] and Elixir-Excelerate [grant number: 676559]. The Research Programme on Biomedical Informatics is a member of the Spanish National Bioinformatics Institute, “Plataforma de Recursos Biomoleculares y Bioinformáticos- Instituto de Salud Carlos III” [grant number: PT13/0001/0023], of the PE I+D+i 2013-2016, funded by “Instituto de Salud Carlos III” and “Fondo Europeo de Desarrollo Regional”. The “Departamento de Ciencias Experimentales y de la Salud” is a “Unidad de Excelencia María de Maeztu”, funded by the “Ministerio de Economía y Competitividad” (reference number: MDM2014-0370)